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ABSTRACT
Proteome homeostasis is crucial for optimal cellular function and survival in the face of various stressful impacts. This 
entails preservation of a balance between protein synthesis, folding, degradation, and trafficking collectively termed pro-
teostasis. A hallmark of proteostasis failure, which underlies various diseases, is enhanced misfolding and aggregation 
of proteins. Here we adapted the measurement of protein turbidity, which is commonly used to evaluate aggregation of 
single purified proteins, for monitoring propensity for aggregation of the entire soluble cellular proteome incubated in 
vitro for several hours. We show that over-expression of an aggregation-prone protein or applying endoplasmic-reticulum 
(ER) stress to either cells in culture or to the intact organism, Drosophila, enhances the rise in turbidity of the global 
soluble proteome compared to untreated cells. Additionally, given that Alzheimer’s disease (AD) is known to involve ER 
stress and aggregation of proteins, we demonstrate that the soluble fraction of brain extracts from AD patients displays 
markedly higher rise of global proteome turbidity than in healthy counterparts. This assay could be valuable for various 
biological, medical and biotechnological applications.
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INTRODUCTION
Protein aggregation is associated with various diseases of unrelated 
etiologies. It accompanies various extracellular and intracellular stresses, 
such as endoplasmic-reticulum (ER) stress, enhanced unfolded protein 
response (UPR) activity, proteasome malfunction, heat shock and 
oxidative stress [1-3]. An increasing number of proteins are identified 
as intrinsically disordered even in their native conformation, making 
them especially prone to aggregation [4]. Typical examples include 
Amyloid-β (Aβ) and tau, involved in Alzheimer’s disease (AD), α-sy-
nuclein (α-syn) the main agent in Parkinson’s disease (PD) and PrP in 
prion diseases [5]. Aggregates of tumor suppressor proteins such as p53 
and pVHL have also been documented and were related to the process 
of transformation [6,7].
A protein may become prone to aggregation due to various char-
acteristics of its structure: its native structure may be metastable (i.e. 
intrinsically disordered) [8], missense mutations may alter its confor-
mation and partial degradation may result in aggregative fragments 
[9,10]. The aggregation process begins with the formation of aggregation 
nuclei, whose growth is the rate-limiting step of this process [11]. Once 
a nucleation seed is formed, aggregate growth is thought to proceed 
rapidly by further association of either monomers or oligomers to the 
formed nucleus [12]. A protein may aggregate along various pathways 
depending on the environmental conditions and types of cellular stress 
[13]. Usually, misfolding and consequent aggregation of a protein leads 
to loss of functionality. In addition, the aggregates themselves may 
be cytotoxic [14]. Importantly, increasing evidence suggests that the 
aggregating protein could affect other proteins leading to loss of their 
function. For example, misfolded prion (PrPSc) recruits, and corrupts 
normal PrPc [15]; mutant p53 was shown to co-aggregate with its par-
alogs p63 and p73 [16]; oligomers of phosphorylated Tau were found 
to co-aggregate with α-syn revealing molecular cross-talk between dif-
ferent aggregation pathways involved in neurodegeneration [17]. Thus, 
aggregation of a single protein species can lead to aggregation cascade 
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involving additional proteins, resulting in broad impact on the cell.
A complex cellular machinery for ensuring proteostasis has evolved to 
handle misfolding and consequent aggregation of proteins. It commences 
with the recognition of the misfolded protein, and the attempt to restore 
its normal folding (e.g., by molecular chaperones). If not successful 
the UPR is activated together with stress-responsive signaling aimed at 
targeting the protein for either degradation, sequestration in inclusion 
bodies, or activation of apoptosis [1,18,19].
Overloading the machinery involved in maintaining proteostasis 
with a specific misfolded protein can, indirectly, lead to its inability to 
handle aggregation of other proteins, especially those that are intrinsi-
cally unstable and prone to aggregation (e.g., p53) [20].
Current approaches for monitoring protein aggregation rely on isolat-
ing the specific protein of interest. They include use of conformational 
sensitive dyes (e.g., Thioflavin-S/T), direct spectroscopy (e.g., FTIR, 
NMR, TEM and SEM), light scattering (e.g., turbidity, CD and DLS or 
SLS). In addition, aggregation sensitive reporters (e.g., FRET), native 
and denatured acryl amide gels have been employed. Indirect methods 
for evaluating protein aggregation can also be used such as monitor-
ing the activation level of chaperones, or relying on various readouts 
of the activation of the UPR machinery, ER-stress and proteasomal 
degradation [21].
Here we present a facile method for monitoring global propensity for 
aggregation of proteins in the cell, using turbidity assay of the soluble 
fraction of total protein extracts incubated in vitro for several hours. 
Employing protein extraction protocols commonly used for each of the 
following we show that over-expression of a specific protein or applying 
ER stress to either cells in culture or to the intact organism, Drosophila, 
enhances the rise in proteome turbidity compared to untreated cells. 
Given that AD is known to involve aggregation of amyloidogenic 
polypeptides and enhanced ER stress [22,23], we demonstrate that 
soluble fractions of brain cells from postmortem AD patients display 
markedly higher rise of proteome turbidity than extracts from healthy 
counterparts. This assay could be valuable for a broad range of appli-
cations in biomedicine and biotechnology.
METHODS
Drosophila strains and genetics
The following fly strains were used: Oregon R (OR) served as wild-
type flies. The control flies expressing only the relevant Gal4 driver were 
obtained by crossing OR flies with the flies carrying the appropriate 
GAL4 driver (Table 1).
Tau-expressing and Aβ42-expressing flies shown in Table 1 were 
generated from lines # 51362 (w [1118]; P{w [+mC] = UAS-Tau.wt}1.13) 
and # 33769 (w [1118]; P{w [+mC] = UAS-APP.Abeta42.B}m26a), 
respectively (Bloomington Drosophila stock center, Indiana University).
Wild type human pVHL and its N78S, F136L and Y98H mutant 
versions were cloned into the pUASTattB vector by standard procedures 
[6] using EcoRI and XhoI restriction enzymes. These expression vectors 
were used to transform the phiC31-integrase-mediated recombination 
flies [25] (BestGene, CA). We used transgenic strains carrying stable 
insertions on chromosome 3. Tubulin-Gal4 was kindly provided by 
O. Gerlitz (Hebrew University of Jerusalem, Israel), and was used for 
inducing UAS-dependent ubiquitous expression.
All strains were reared on standard cornmeal-molasses medium at 
25°C. Experiments were carried out at 25°C. Adult offspring (F1) from 
the crosses were collected up to 9 days after the beginning of their eclo-
sion at 25°C in order to avoid offspring from the next generation (F2).
Table 1. Genotypes of flies used for protein extraction.
Protein over-
expression
Females Males
hTAU yw,P{GMR-Gal4, w+}/
FM7a; P{UAS-tau(wt)-
1.13,w+}/CyO
yw,P{GMR-Gal4, w+}; 
P{UAS-tau(wt)-1.13,w+}/
CyO
hAβ yw,P{GMR-Gal4, w+}/
yw,P{GMR-Gal4, w+}; 
P{UAS-APP.Aβ42.B}
m26a/CyO [24]
yw,P{GMR-Gal4, w+}; 
P{UAS-APP.Aβ42.B}
m26a/CyO [24]
Control yw,P{GMR-Gal4, w+}/+; 
+/+
yw,P{GMR-Gal4, w+}; 
+/+
Cell culture
SH-SY5Y (human neuroblastoma) cells were obtained from the 
American Type Culture Collection (ATCC) and cultured in DMEM 
F12 1:1 containing 10% fetal bovine serum, 2 mM L-glutamine, 1000 
U/ml penicillin-G, 1 mg/ml streptomycin sulfate and 1 mM sodium 
pyruvate at 37°C under 5% CO2 (v/v). To generate SH-SY5Y cells stably 
expressing HA-tagged proteins, we used a CMV retroviral system. The 
infected cells were selected using puromycin.
Human brain tissue
Frozen autopsied frontal cerebral cortices, five AD and five controls 
were kindly provided by the University of Manchester Brain Bank. The 
age, gender and Braak stages of these samples are listed in Table 2. 
The number of samples per group was N = 5.
The use of the human brain tissue was in accordance with all relevant 
Codes of Practice of the Human Tissue Authority (HTA) and approved 
by the institutional review board of Tel Aviv University and of the 
University of Manchester Brain Bank.
Table 2. Human brain tissue of Alzheimer’s disease and control cases 
used in this study.
Case # Gender Age at 
death (yr)
Braak 
stage
Brain bank
identifier #
Con 1 F 82 0 06/19
Con 2 F 79 1 06/08
Con 3 F 85 0 07/07
Con 4 F 82 1 06/12
Con 5 M 86 0 07/06
AD 1 M 45 5–6 92/47
AD 2 M 44 5–6 92/20
AD 3 F 53 5–6 91/76
AD 4 F 86 6 03/19
AD 5 M 74 6 97/24
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Protein extraction
Drosophila: Collected whole flies or fly heads were homogenized 
in 1:1 volume of extraction buffer [5 mM MgCl2, 1 mM DTT, 1 mM 
PMSF, 1 × Complete protease inhibitor cocktail (Roche), 1 × phosphate 
buffer saline (PBS), pH 7.5]. The samples were centrifuged for 30 min 
at 20000 g at 4°C for removal of non-soluble particles and the resulting 
supernatants were used for further analyses [26].
Cell culture: cells were grown to 80%–100% confluence in 100 mm 
culture plates. The plates were rinsed with cold PBS and cells were 
extracted in buffer (5 mM MgCl2, 1 mM DTT, 1 mM PMSF, 1 × Com-
plete protease inhibitor cocktail (Roche), 1 × PBS, pH 7.5) followed 
by three cycles of sonication on ice. Lysed cells were centrifuged for 
15 min at 20000 g at 4°C for removal of non-soluble particles and the 
resulting supernatants were used for further analyses. Protein extraction 
from cell culture was adapted from [27,28].
Brain tissue: was homogenized using BULLET BLENDER® (Next 
Advance, Inc.) after several washes with PBS in ice-cold homogeniza-
tion buffer, consisting of 50 mM Tris–HCl, pH 7.4, 8.5% sucrose, 2.0 
mM EDTA, 100 mM GlcNAc and Complete protease inhibitor cocktail 
(Roche). The homogenates were centrifuged at 20000 g for 20 min at 
4°C for removal of non-soluble particles and the resulting supernatants 
were used for further analyses. Protein extraction from cell culture was 
adapted from [29,30].
Protein concentration was measured using Bradford or BCA reagents 
(Sigma-Aldrich).
Turbidity measurements
Supernatants were diluted in relevant extraction buffer to a desired 
concentration 1 mg/ml. Appropriate number of biological (n > 3) and 
technical (n > 3) replicates were conducted for each experiment. For 
choosing the wavelength at which turbidity will be measured we ex-
amined the absorbance spectra of total soluble protein extracts and 
observed no significant peak at 340 nm (Fig. S1). Therefore turbidity was 
monitored at 340 nm, using a Synergy HTX plate reader (Biotek) and 
polypropylene 96-well plates (Corning) in 100 μl volume. Plates were 
shaken gently for 5 s prior to each measurement cycle and incubated at 
37°C. All optical densities were measured at 340 nm wavelength and 
their first measurement (O.D.(T0)) was subtracted in order to eliminate 
background absorbance of the samples.
Quantitative periodic acid Schiff staining
Prior to experiment, samples were adjusted to identical protein con-
centrations (measurement was performed by BCA reagent, PIR-2325, 
Pierce). To 25 µl protein lysate solution (2 mg/ml) in each well of a 96 
well plate, 120 µl of 0.06% periodic acid solution (375810, Sigma-Al-
drich) in freshly made 7% acetic acid were added. The microtiter plate 
was covered with a plastic seal and incubated at 37°C for 1.5 h without 
shaking. The plate was allowed to cool to room temperature before 100 
µl of Schiff’s reagent were added to each well (395-2, Sigma-Aldrich). 
The microtiter plate was covered again with a plastic seal and was 
shaken for 5 min. Color was allowed to develop at room temperature 
for additional 30 min before absorbance was recorded at 550 nm.
8-anilino-1-naphthalene sulfonic acid fluorescence 
studies
Fluorescence emission at 460/40 nm was generated with excitation 
wavelength of 350 nm using a Synergy HTX plate reader (Biotek) and 
polypropylene 96-well plates (Corning) in 100 μl volume. The first 
solution contained 10 µM 8-anilino-1-naphthalene sulfonic acid (ANS) in 
PBS buffer. The other solutions were similar and contained total soluble 
protein extract at a final concentration of 1 mg/ml. Baseline corrections 
were made with buffer lacking proteins and ANS. Appropriate number 
of biological (n > 3) and technical (n > 3) replicates were conducted 
for each experiment. Plates were shaken gently for 5 s prior to each 
measurement cycle and incubated at 37°C.
Immunoblotting
Laemmli sample buffer (BioRad) was added to equal amount of 
total protein extract from each sample, followed by boiling for 10 min, 
centrifugation for 5 min at 14000 RPM and analysis by SDS-PAGE 
and Western blot. Protein extracts were resolved on 4%–20% gradient 
SDS-PAGE (GeBA, Israel) and transferred on to PVDF membrane using 
iBlot 7-Minute Blotting System (Life Technologies). The membrane 
was blocked for 1 h in blocking solution (5% milk powder, 0.02% so-
dium-azide in 1 × TBS), and then incubated with the primary antibody 
diluted in blocking solution. The membrane was then washed 3 times 
for 15 min each in TTBS (0.1% Tween-20 in 1 × TBS), incubated for 1 
h with the secondary antibody and washed 3 times for 10 min in TTBS. 
The membrane was developed using EZ-ECL (Biological Industries, 
Israel), according to the manufacturer’s instructions, and exposed to 
Fuji Medical X-Ray Film for up to 5 min. Films were developed using 
Kodak X-OMAT 2000.
Antibodies used: anti β actin 1:5000 (ab8224, abcam), anti Tau pro-
tein 1:1000 (5A6, Hybridoma bank), anti Aβ 1:500 (6E10, Biolegend), 
anti pVHL 1:1000 (VHL40, Santa Cruz Biotechnology, Inc.) anti-HA 
1:1000 (sc7392 Santa Cruz Biotechnology, Inc.) anti-TDP43 1:1000 
(AP-10782-2 Proteintech).
Secondary antibodies used were from Santa Cruz Biotechnology, Inc. 
(horseradish peroxidase-coupled goat anti-mouse and goat anti-rabbit 
antibodies).
Reverse transcription and real-time PCR
Total RNA from 10 adult flies was isolated with RNeasy mini kit with 
on-column DNase digestion (Qiagen). First-strand cDNA was generated 
by using the Verso cDNA Kit (Thermo). Real-time polymerase chain 
reaction (PCR) was performed in triplicate with KAPA Fast SYBR 
master mix (KAPA Biosystems) and the StepOnePlus™ Real-Time 
PCR Systems (Life Technologies, Israel). Primers for rp49, pVHL were 
purchased from HyLabs (Israel). All values were normalized to the level 
of rp49 mRNA abundance and to the wild type (Oregon R) flies. Each 
primers pair was calibrated using the Absolute Quantification program 
with increasing concentrations of cDNA, from 1:32 to 1:1 dilutions of 
the original cDNA. Primers used were: rp49 (forward 5’- ACC GAT 
GTT GGG CAT CAG ATA-3’ ; reverse 5’- TAA GCT GTC GCA CAA 
ATG GC-3’) and pVHL (forward 5’ CCT CCC AGG TCA TCT GCA 
AT-3’; reverse 5’- GTT AAC CAG AAG CCC ATC GTG TG-3’).
Compound preparation, concentration and treatment
Stock solutions of tunicamycin or thapsigargin (Sigma-Aldrich) 
were prepared in dimethylsulfoxide. For tunicamycin treatment, flies 
were grown, in the dark, for their entire life time on cornmeal-molasses 
medium containing 10 μM tunicamycin. They were collected 7 d after 
eclosion from the pupal case, cells were exposed to 10 μM tunicamycin 
for 24 h. For thapsigargin treatment, cells were exposed to 10 μM for 
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24 h. The control cells or flies received the same amount of solvents.
Statistics
All experiments were repeated three times or more and the signif-
icant difference was calculated using a student t-test and ANOVA for 
evaluating statistical significance of the observed differences. *P < 0.05, 
**P < 0.01, ***P < 0.001.
Figure 1. Global proteome turbidity of flies treated with tunicamycin. 
A. Validation of inhibition of glycosylation by tunicamycin using periodic 
acid-Schiff which stains protein glycans, in treated versus untreated flies. B. 
Turbidity levels of total soluble protein extracts (1 mg/ml) from flies reared 
on culture medium lacking or containing tunicamycin. All optical densities 
were measured at 340 nm and their first measurement (O.D. (T0)) was 
subtracted in order to eliminate background absorbance of the samples. 
Appropriate number of biological (n = 4) and technical (n = 3) replicates 
were conducted for each experiment. **P < 0.01.
RESULTS AND DISCUSSION
Induced ER stress results in elevated global proteome 
turbidity in Drosophila model
To examine the effect of ER stress on global accumulation of 
misfolded/unfolded proteins we used tunicamycin. Tunicamycin is 
an inhibitor of the UDP-N-acetylglucosamine-dolichol phosphate 
N-acetylglucosamine-1-phosphate transferase (GPT), thus blocks the 
initial step of glycoprotein biosynthesis in the ER [31]. As a result, 
misfolded glycoproteins accumulate in the ER, leading to ER stress 
[31]. Consequently the misfolded proteins are translocated to the cy-
tosol were they are degraded by the ubiquitin-proteasome machinery 
(ER-associated degradation - ERAD). We postulated that accumulation 
of misfolded and unfolded proteins in the ER lumen will lead to higher 
global aggregation. Wild type (Oregon R, OR) Drosophila were fed on 
either tunicamycin-containing medium or on regular medium through-
out their lifetime and total proteins were extracted using a standard 
protein extraction procedure. Insoluble components, likely comprising 
preexisting protein aggregates, membrane particles and other cell debris 
were removed by centrifugation. The soluble fraction was subjected to 
periodic acid-Schiff staining, which detects protein glycans, showed 
that tunicamycin treated flies had lower level of soluble glycoproteins 
as expected due to the inhibition glycosylation by the drug (Fig. 1A). 
Turbidity analysis of the total proteome in the soluble fraction indicated a 
modest increase of turbidity over time in the samples from the untreated 
control flies, reflecting a basal propensity for aggregation. In contrast, 
turbidity of extracts from tunicamycin treated flies was markedly higher 
with a significant difference between the two samples noticeable already 
9.5 h after the beginning of measuring turbidity (Fig. 1B). Thus, the 
turbidity assay provides a quick and easy readout for the aggregation 
propensity of the global cellular proteome.
Expression of aggregation-prone proteins enhances 
global proteome turbidity
The proteostasis paradigm predicts that over-expression of specific, 
aggregative protein may cause ER stress leading to aggregation of other 
aggregation-prone proteins [2]. This should be detectable by monitoring 
global soluble protein turbidity. To that end, we examined the effect on 
global protein turbidity of three different aggregative human proteins 
overexpressed in Drosophila: Tau, Aβ and pVHL.
Tau is an aggregative amyloidogenic protein, and is a hallmark 
of AD. Expression of human Tau was targeted to the fly eyes via the 
UAS-Gal4 system using the GMR-Gal4 driver [32].
Global proteome turbidity of the soluble fraction from fly head 
extracts was found to be significantly higher in samples from flies ex-
pressing human Tau compared to control flies which carry GMR-Gal4 
only (Fig. 2A and 2B). This was true for both sexes, yet males displayed 
higher values than females. This is expected since the GMR-Gal4 driver 
resides on the X chromosome which is expressed in male files consid-
erably higher than in females [33] and is evident as 1.45 higher level 
of the Tau protein in Tau expressing males than in females (Fig. 2C).
Over expression of the Alzheimer’s-associated Aβ polypeptide in 
Drosophila eyes also resulted in significantly enhanced global proteome 
turbidity of the soluble fraction from head protein extracts compared to 
samples from control flies carrying GMR-Gal4 only (Fig. 3). This was 
true for both sexes. The higher turbidity observed in females is because 
they carry two copies (homozygous) of the GMR-Gal4 driver used 
whereas males carry only one copy. This is reflected in higher expres-
sion of the Aβ protein (1.2 fold higher) in the tested females (Fig. 3C).
We wished to obtain an independent measure of protein aggregation 
in these experiments. To that end, in parallel to the turbidity assay, we 
employed a fluorophore. Fluorophores, e.g., Thioflavin-T, are routinely 
used for evaluating protein aggregation. Here we used ANS commonly 
employed for monitoring hydrophobic aggregation. The fluorescent 
properties of ANS change as it binds to hydrophobic regions on the 
protein surface [34]. Figure 4 shows that ANS fluorescence can detect 
differences in propensity for aggregation between the experimental and 
control samples (expressing vs. non expressing the aggregative proteins 
examined, Aβ or Tau, respectively). Note that there is some aggregation 
in the control sample (expressing only GMR-Gal4) but this GMR-Gal4 
exists also in the experimental samples (which also express Aβ or Tau), 
underscoring the fact that this measurement is relative and should 
always be done with the appropriate control sample. Interestingly, as 
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Figure 4 indicates, measuring global turbidity is more sensitive than 
ANS fluorescence of the samples. The change in turbidity is primarily 
due to aggregation of proteins since prior treatment of the samples with 
either proteinase K or trypsin reduces turbidity markedly (Fig. S2).
Figure 2. Global proteome turbidity of flies over expressing Tau 
protein via GMR-Gal4. A and B. Turbidity levels of the soluble fraction 
of total protein extracts (1 mg/ml) from flies over expressing Tau protein 
in females (A) versus males (B). All optical densities were measured at 
340 nm and their first measurement (O.D.(T0)) was subtracted in order 
to eliminate background absorbance of the samples. ♀ = females, ♂ = 
males. C. Western blot analysis showing the levels Tau protein in whole 
protein extracts from flies heads. β actin was used as loading control. The 
ratio between Tau protein and β actin is indicated. Appropriate number of 
biological (n = 5) and technical (n = 3) replicates were conducted for each 
experiment. ***P < 0.001.
We next examined global protein turbidity following expression in 
flies of another aggregative protein, namely the wild type human pVHL 
and its three mutant versions. pVHL is a tumor suppressor protein 
whose loss of function is associated with the VHL cancer syndrome 
[35]. Wild type pVHL has a molten globule conformation and is prone 
to aggregation [36]. We previously showed that various mutations in 
pVHL differentially enhance its aggregation propensity in vitro [6]. 
For example, N78S and F136L are structural mutations which alter the 
folding of pVHL, and leading to higher aggregation propensity than 
wild type pVHL. Y98H has only a slight effect on pVHL folding and 
aggregation, yet directly affects its HIF1-a binding site, hence displays 
severe loss-of-function [6].
Figure 3. Global proteome turbidity of flies over expressing Amyloid-b 
protein via GMR-Gal4. A and B. Turbidity levels of soluble protein extracts 
(1 mg/ml) from flies over expressing Aβ protein females (A) versus males (B). 
All optical densities were measured at 340 nm and their first measurement 
(O.D.(T0)) was subtracted in order to eliminate background absorbance of 
the samples. ♀ = females, ♂ = males. C. Western blot analysis showing 
the levels Aβ protein in whole protein extract from flies heads. β actin 
was used as loading control. The ratio between Aβ protein and β actin is 
indicated. Appropriate number of biological (n = 3) and technical (n = 3) 
replicates were conducted for each experiment. *P < 0.05.
Wild type pVHL and the three different mutant versions were over-ex-
pressed ubiquitously in flies using the tubulin Gal4 driver. Global tur-
bidity of total soluble proteins extracted from whole fly bodies indicated 
that all four variants of pVHL examined yielded higher turbidity levels 
than flies from the parental strain expressing only tub-Gal4 (Fig. 5A). 
Turbidity levels of the samples from F136L- and Y98H- expressing flies 
was 5 and 2.5 fold higher than from flies expressing wild type pVHL, 
in accordance with their high and moderate propensity to aggregate, 
respectively [6]. Surprisingly, samples from flies expressing the N78S 
mutant displayed similar turbidity levels as samples from flies expressing 
wild type pVHL. This may be due to the markedly low expression level 
of the N78S protein in the fly soluble fraction (Fig. 5B). Real time qPCR 
analysis indicated that all pVHL transgenes used had similar mRNA 
levels (Fig. 5C). Thus, the N78S mutant protein, which was shown to 
have short half-life [37], is rapidly degraded thus contributing less to 
proteome turbidity.
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Figure 4. Global proteome turbidity of soluble extracts from flies over 
expressing Aβ or human TAU by GMR-Gal4. A. Turbidity levels of soluble 
protein extracts (1 mg/ml) from flies over expressing Aβ or Tau proteins. All 
optical densities were measured at 340 nm and their first measurement (O.D. 
(T0)) was subtracted in order to eliminate background absorbance of the 
samples. B. ANS fluorescence analysis of soluble protein extracts (1 mg/ml) 
from flies over expressing Aβ or Tau proteins. Note that errors bar is very small 
and therefore invisible. Appropriate number of biological (n = 3) and technical 
(n = 3) replicates were conducted for each experiment.
Induced ER stress in cultured cells results in elevated 
global proteome turbidity
To examine whether the results obtained in the fly model could be 
recapitulated also in human cells in culture, we treated neuroblastoma 
cells (SH-SY5Y) with tunicamycin or thapsigargin, both of which 
cause ER stress. Turbidity levels of soluble total protein extracts from 
cells treated with either drug were significantly higher (2 fold) than in 
untreated cells (Fig. 6A and 6B), in accord with the results from flies.
We next examined the effect of over-expression of an aggregative 
protein in cultured cells on the propensity of the total soluble proteome to 
aggregate, using the turbidity assay. To that end we produced neuronal cells 
(SH-SY5Y) stably expressing α-synuclein or TDP43 or (Fig. 6C). a-synu-
clein is associated with Parkinson’s disease and the TAR DNA-binding 
protein 43 (TDP43) is involved in amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia (FTLD-TDP) [38,39]. Significantly higher 
global turbidity levels (> 12 fold) were found in the soluble fraction 
from cells expressing a-synuclein, in comparison to naive SH-SY5Y 
cells (Fig. 6D). For TDP43 we expressed two versions—the wild type 
TDP43 and a mutant A315T version, associated with rare hereditary 
form of ALS known to have a more severe neurotoxic phenotype, which 
has higher propensity for aggregation than the wild type counterpart 
[40]. Indeed, cells expressing A315T exhibited ~2.5 fold higher level 
of turbidity than cells expressing wild type TDP43 protein and ~10 fold 
higher than naïve SH-SY5Y cells (Fig. 6D).
Figure 5. Global proteome turbidity of soluble fraction from flies over 
expressing human VHL protein by tubulin Gal4. A. Turbidity levels of 
total protein soluble extracts (1 mg/ml) from flies expressing the wild type 
VHL protein or its mutant versions. All optical densities were measured at 
340 nm and their first measurement (O.D.(T0)) was subtracted in order to 
eliminate background absorbance of the samples. B. Western blot analysis 
showing the levels of VHL protein in whole soluble protein extract from flies. 
β actin was used as loading control. C. Real-time qPCR analysis of pVHL 
transcript in the flies over expressing human VHL protein via tub-Gal4. 
Expression of each gene was normalized to rp49 gene which was used 
as an internal control. Bars represent SEM (n = 5). Appropriate number 
of biological (n = 3) and technical (n = 5) replicates were conducted for 
each experiment. ***P < 0.001.
Global protein turbidity is increased in brains of Alzhei-
mer’s disease patients
The brain of AD patients displays characteristic aggregates composed 
mainly of Aβ or Tau proteins. We examined whether global protein 
turbidity is altered in the soluble fraction of extracts from postmortem 
AD patient brains (Fig. S3 shows a western blot of the clear supernatant 
and the pellet fractions from three independently prepared human brain 
tissue extracts, demonstrating that the supernatant contains mainly the 
soluble fraction). Figure 7 shows that extracts of frontal cortex from 
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AD patients displayed significantly higher (2-fold) turbidity level than 
samples from brains of healthy age matched controls demonstrating 
that this assay can easily and quantitatively detect symptoms of protein 
misfolded diseases.
Figure 6. Global proteome turbidity of neuronal cells (SH-SY5Y). A. Turbidity levels of total soluble protein extracts (1 mg/ml) from neuronal cells (SH-
SY5Y) treated with thapsigargin or untreated cells as a control. B. Turbidity levels of total soluble protein extracts (1 mg/ml) from neuronal cells (SH-SY5Y) 
treated with tunicamycin or untreated as a control. C. Western blot analysis showing the levels of α-synuclein, TDP43 or its mutant version TDP43 A315T 
protein in whole protein extract from SH-SY5Y cells. β actin was used as loading control. D. Turbidity levels of total soluble protein extracts (1 mg/ml) from 
neuronal cells (SH-SY5Y) stably expressing TDP43 or its mutant version TDP43 A315T or α-synuclein. All optical densities were measured at 340 nm 
and their first measurement (O.D. (T0)) was subtracted in order to eliminate background absorbance of the samples. Appropriate number of biological 
(n = 3) and technical (n = 3) replicates were conducted for each experiment. ***P < 0.001.
Figure 7. Global proteome turbidity is increased in brains of Alzhei-
mer’s disease patients. Turbidity levels of total soluble protein extracts 
from 10 brains (5 AD patients, 5 controls). All optical densities were mea-
sured at 340 nm wavelength and subtracted with their first measurement 
(O.D.(T0)) in order to eliminate background absorbance of the samples. 
Appropriate number of biological (n = 5) and technical (n = 3) replicates 
were conducted for each experiment. **P < 0.01.
We expect other protein misfolding diseases (e.g., Parkinson’s disease 
and Huntington’s disease, type 2 diabetes, some forms of atherosclerosis 
and various types of cancer [41]) to display changes in total proteome 
turbidity as revealed for AD patients by the assay described here. It 
will be interesting, in the future, to identify the proteins composing 
the aggregates that cause the enhanced turbidity, which may have 
been recruited by the nucleating aggregative protein. Total proteome 
turbidity can serve as a diagnostic tool for monitoring progression of 
protein misfolding diseases. When combined with the identification 
of the aggregated proteins it could serve as a novel biomarker. This 
should be particular feasible using body fluids in which the aggregates 
accumulate such as cerebrospinal fluid and blood for example in neu-
rodegenerative diseases and serum amyloidosis.
In conclusion, we present a facile and practical method for monitoring 
aggregation propensity in the natural cell environment, by applying the 
turbidity assay to total protein extracts. It is important to bear in mind 
that this measurement is relative.
Collectively the results described above, indicate that the propen-
sity to aggregate of the global soluble proteome can be detected under 
various physiological conditions even in the absence of an apparent 
stress or aggregation seed as evident from the results of all of the con-
trols used (untreated samples and naïve cells). It probably reflects the 
relative extent at which the cellular milieu is prone and conducive to 
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protein aggregation. Turbidity levels and kinetics are therefore relative 
and should be monitored only in comparison to an appropriate control. 
Furthermore, standard protein extraction protocols are often specific 
for a given tissue or organism, precluding comparison of absolute 
turbidity levels between samples from distinct sources. We observed 
that nucleation by individual aggregative proteins may enhance global 
protein aggregation. This implies that under various stresses, which 
often occur in various diseases, aggregates of the disease-related pro-
teins may function as a seed and recruit other proteins thus enhancing 
global proteome aggregation.
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